Agomelatine

Agomelatine (BAN, rINN; trade names Valdoxan, Melitor, Thymanax) is a melatonergic antidepressant developed by the pharmaceutical company Servier. It is marketed for the treatment of major depressive disorder and has been reported to not produce discontinuation syndrome and have no sexual side effects compared to SSRIs, SNRIs and the older tricyclic antidepressants. Agomelatine may also have positive effects on sleep. Agomelatine is a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist. Binding studies indicate that it has no effect on monoamine uptake and no affinity for α, β adrenergic, histaminergic, cholinergic, dopaminergic and benzodiazepine receptors.

Properties:

Appearance & Physical State: white solid

Density: 1.109g/cm3

Boiling Point: 478.8ºC at 760 mmHg

Melting Point: 107-109ºC

Flash Point: 243.4ºC

5-HT Receptor Inhibitors Related Products:

Iloperidone; Olanzapine; Clozapine; Duloxetine hydrochloride; Duloxetine; Alosetron hydrochloride; Palonosetron hydrochloride; Lurasidone; Lurasidone hydrochloride; Ramosetron Hydrochloride; Atomoxetine hcl

[1]. Pan L, Kardono LB, Riswan S, Chai H, Carcache de Blanco EJ, Pannell CM, Soejarto DD, McCloud TG, Newman DJ, Kinghorn AD. Isolation and characterization of minor analogues of silvestrol and other constituents from a large-scale re-collection of Aglaia foveolata. J Nat Prod. 2010 Nov 29;73(11):1873-8.

[2]. Zajecka J, Schatzberg A, Stahl S. et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010 Apr;30(2):135-44.

[3]. Randy A Sansone, Lori A Sansone. Agomelatine A Novel Antidepressant. Innov Clin Neurosci. 2011 November; 8(11): 10-14.